REMARKS

Applicants have attached an abstract on a separate sheet of paper as required by U.S. practice. Applicants have amended the specification for purposes of adding the priority information. Claim 9 has been amended to remove multiple dependencies. Claim 24 has been added. Claims 16, 17, 18, 19, and 20 were canceled from the present application without prejudice to the re-filing of the claims in a continuation application. Claims 1-24 are pending in the application. No new matter has been added. It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Date: April 19, 2005

Karen L. Prus

Attorney of Record, Reg. No 39,337

GlaxoSmithKline

Corporate Intellectual Property Five Moore Drive, PO Box 13398

Research Triangle Park, NC 27709-3398

Telephone: 919-483-2192

Fax: 919-483-7988